Outside the established legal framework of intellectual property rights, countries have pursued multiple pathways to protect and promote traditional medicine. As Tibetan medicine is a late entrant into commercialization, the proposals to propertize This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
| INTRODUCTION
The structure and dynamics of innovation in medicine often tends to be taken in isolation from the broader framework of socio-economic systems. It is narrowly defined as science and technology driven and competition induced research on drug and devices, whose emergence is rather disconnected from the system through which health services are often delivered (Consoli & Mina, 2009 ). The stereotyped definition of innovation at times can create tensions and lead to disruption of the social innovation dynamics in indigenous medicines, as frequently witnessed in new organizational regulations like Good Manufacturing Practices (GMPs). Many indigenous practitioners develop and transmit knowledge from generation to generation in which individuals can distinguish themselves as informal creators or innovators, separate from the community.
Indigenous medical systems are shaped from diverse forms of interference, struggle, and creative adaptations.
Some of them extend beyond one community, some are confined within a locality, some are of transnational existence, some may or may not link to the local eco-systems, some are of migratory origin-all makes the practice, development, transmission, and ownership very curious and complex. Many new theoretical approaches within health research consider healthcare systems as knowledge economies rather than simple assemblages of technical services, personnel, and goods and institutions (Bloom & Standing, 2008; Leonard, 2002) . Not only does indigenous medicine compete with biomedicine embedded in the capitalist world system (Baer, Singer, & Johnsen, 1986) , but it looks beyond the operational tools that biomedicine provides in shaping up the pathways for further research and development of new medicines and challenge the protection mechanisms usually associated with the same. These characteristics of indigenous medical systems may also raise doubts about the "one fit for all" solutions of protection emerging at various international negotiation forums (Mashelkar, 2001 ).
For emerging industrial medicines like Tibetan medicine, 1 any minor transformation in the process of production, organizational aspects, product variety, or elements that enable access to new or broader markets (elements of Schumpeterian conceptualization of innovation) may bring considerable impact and challenges on its development.
Some of them are very "modest innovations" that are generally overlooked and ignored in official science and technology indicators. In spite of being non-technological, they translate into substantial increase in the ability to produce and compete on a sustained basis, generating income and better living standards for those involved and create continuity in translating and popularizing the knowledge. This process of enhanced production is further incentivized upon the ability to protect and nurture those innovations in the petty-commodity production process.
These innovations will happen even if the expected economic benefits from the future are relatively low. The "exchange value" they create depends more on the ability to provide the medicines at a cheaper cost to those required patients or consumers and hence much closer to the actual "use value" of the knowledge. These innovations are well below the radar of scientific and capital investment of larger scale, which potentially create massive exchange value.
These below the radar (BtR) innovations (Clark et al., 2009 ) are the prime movers of the Tibetan medical knowledge especially when it comes to public health of the communities they serve. For instance, in Ayurvedic medicine, social innovations and the reformulated practices known as neo-traditional innovations offer larger possibilities in public health practices (Madhavan, 2014; Pordie & Gaudilliere, 2014) .
The processes of economic globalization and transnational trade regulations obviously raise the question as to whether the international protection of intellectual property matter to "below the radar" innovations. This article examines whether and how local property right regimes govern these small innovations in traditional Tibetan medicines in China and India. The paper does not intend to discuss the familiar literature of intellectual property protection of indigenous medicines as many have written on this growing but increasingly confusing topic 2 (Dutfield, 2005; Gopalakrishnan, 2002; Hsiao, 2007; Li & Li, 2007; Oguamanam, 2008a,b ; among many others). Rather, this article attempts to extend this field of research to Tibetan medicine through analyzing the national policy approaches apart from the international negotiations. The interviews with Tibetan physicians from India, China, and Mongolia are used in the article along with the patent documents from published sources to understand various perspectives on innovations and policy implications in this field.
This article proceeds as follows. First, it briefly discusses Tibetan medicine, its historical origins, its makers, and its main features. Second, it explores the forms and examples of innovation investigating the concept of "below the radar innovations." Third, it examines the way in which Tibetan medicine has been considered as a form of economic property. Fourth, it analyses how Tibetan medicine is governed at the national level. Fifth, it illustrates Tibetan medicine as a form of intangible cultural heritage. The concluding section attempts to connect these approaches and make some inferences on the inclusive innovation capabilities of these approaches.
| TIBETAN MEDICINE
In its origins, Tibetan medicine is a synthesis of major scholarly traditions (ayurvedic, Greco-Arabic, and Chinese) and the indigenous knowledge and techniques of treatment developed over many centuries by local medical practitioners.
It is also called "science of healing" (in Tibetan, "Sowa Rigpa" or amchi medicine). For many centuries, it served as an important medical source in Tibet and its neighboring countries (Mongolia, Bhutan, some parts of Nepal and India and in Buddhist regions of Russia). The theory of Tibetan medicine is based on the holistic understanding of human health and its natural environment as detailed in the fundamental Tibetan medical text, Gyüshi (Rgyud bzhi). The treatment modality is predominantly pharmaceutical based but also importantly includes other practices like cupping or "moxibustion-a traditional therapy which consists of burning dried mugwort (moxa) on particular parts on the body,"
as well as dietary and behavioral advice using different kinds of ingredients such as plants, minerals, animals, and metals.
The development of Tibetan medicine across Inner Asia and the Himalayas is largely entwined with the political history of this region. After a period of destruction and repression following the 1959 Tibetan uprising and the Cultural Revolution, Tibetan medicine in China was rehabilitated with state support from 1980s on wards and rapidly commercialized and modernized since the 1990s. In the Tibetan exile in India, the Tibetan medicine has been directly linked to the Tibetan nationalistic agenda as a core symbol of Tibetan identity providing a particular context for its institutional and commercial development (Kloos, 2013 (Kloos, , 2016 . In Mongolia, Sowa Rigpa was the dominant healthcare resource until 1924, when Mongolians embraced a Soviet-style socialist reform program, which championed technological modernization along largely western lines. Soviet-style biomedicine became the only legitimate medical system, and all other competitors were legally restricted (Janes & Hilliard, 2008) . In the post socialist context of Mongolia, from 1990 onwards, the health authorities started rebuilding a system of Traditional Mongolian medicine with the state support and integrated it into the national healthcare system. Mongolian medicine is based on the same textual source (Gyushi) as of Tibetan medicine and hence identical theory and similar practice. In the contemporary form of Mongolian medicine, the Tibetan theories and practices have a major role.
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Traditionally, Tibetan medicines are collected and manufactured by practitioners themselves. Production of Tibetan medicine has evolved from manual compounding to systematic, standardized mass production in the modern industrial context. For example, in Tibet Autonomous Region (TAR) and other provinces of Tibetan regions in China, the number of physicians practicing Tibetan medicine was over 1200 in 1993, and rose to 5000 in 2010 according to official statistics (Yuan, 2012) , and the industry of Tibetan medicine has grown to the extent that it becomes one of the major pillars of industrial growth of the region with 18 factories having manufacturing standards like Good
Manufacturing Practices (GMP) and 300 state permitted pharmacies (Hsu, 2011) . The Tibet Autonomous Region is a province-level entity of the People's Republic of China. Chinese law nominally guarantees some autonomy in the areas of education and language policy, in practice the region is ruled by a Communist Party-appointed cohort and hence the Chinese Health and drug policies are applicable in the region. Tibetan medical departments were attached to almost all medical institutions within the TAR and the industrial development is advancing at a rapid pace (Craig, 2011; Hofer, 2008; Saxer, 2013) . The situation in countries like Mongolia and India is also quite promising in terms of increasing demand and investment of industrial capital in Sowa Rigpa. Given the expanding commercialization of Sowa Rigpa, countries have developed various rules and regulations for its protection and promotion.
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Contemporary Sowa Rigpa reflects the transnational flows of Tibetan medical theory and practice, the ways in which these flows occur and the political-economic and cultural interests which direct and transform the local practices of Tibetan healing (Janes, 2002) . The globalization of Tibetan medicine may not be understood in its singularity but plurality of practice, the practice being evolved in various spaces of production such as China, Mongolia, India, and
Bhutan. Tibetan medicine is also expanding globally. We need to wait and see in which directions Tibetan medicine unfolds in the West. In fact, questions arise as to whether in Western countries it maintains its traditional meaning as a theory and practice of every day wellness, or whether while consciously carrying the name of the ancient tradition, it is being transformed through markets (Banerjee, 2009 ) into something quite different from its original version. This will essentially invite the familiar challenges of its legitimation through parameters of biomedicine and the larger political economic issues that the other indigenous systems have already been through in the course of their transnationalization process (Pordie, 2010; Reddy, 2002) . This may lead to conceptual shrinkage and limit to therapeutic innovations within Tibetan medicine as in the case of Ayurveda (Banerjee, 2009 ). This may overlook the inherent heterogeneity of practice as assumptions of homogeneity of biological bodies are the very rationale for any pharmaceutical expansion.
| BELOW THE RADAR INNOVATIONS (BTR) IN TIBETAN MEDICINE
In China, the embracing of neoliberal economic principles in pursuit of economic modernization has led to a positioning of traditional medicines including Tibetan medicine in view of the global marketplace. In this "new pluralism," economics has become the dominant discipline in global health (Cant & Sharma, 1999; Janes, 2002) (Schwabl & Vennos, 2015) . This is because Tibetan medicine integration into the Western regulatory framework, which only works for formulas, composed of herbal and mineral substances, while the inclusion of any kind of animal components makes the product registration arduous. This calls for compromise in its terms of substitution. In the meantime, there are many innovative experiences operating below the market and policy radar with in this medical system, that is pioneering and disruptive, which constantly adapt to the local conditions, and add substantially to the development of the sector and bring transformations to the life of those live with it. Moreover, they address the social and environmental concerns that public policy is usually struggling to tackle.
Some of these innovations are able to make a larger impact on the market, while some others are able to provide better health options to the public and in some cases, both. These may include products such as medicines, teas/ nutraceuticals/food supplements. Local companies such as the major Tibetan pharmaceutical manufacturing entity
Men-Tsee-Khang (MTK) in Dharamsala reformulate the traditional recipes of Tibetan knowledge using the Gyushi, as the basic reference point. 4 The resulting herbal products include not only anti-aging cream, anti-fatigue teas, and skin care products but new medicines to address liver failure, mental fatigue, multiple sclerosis, and hepatitis. Some of them are reformulations and many others are even change in content. A Physician from Dharamsala, the second capital of Himachal Pradesh state, in India mentioned that; Multiple types of innovations are prevalent in this sector. One example is the innovation of medicines through simple alterations to fit the geographical locations. In the old texts, the quantity of Aconitum (which itself is poisonous) in the formula for khyung-Inga (The prescription is used for diseases caused by worms, heat disorders, skin diseases etc.) is very high (informed by the personal interviews). Now in India, many physicians mention that they use much less khyung-Inga in their medications so that the patients will not faint. They also noted that Indians get dizzy more easily because of their diet in contrast to Tibetans. Now, since most branch clinics of MTK cater mostly to Indian patients, the institute took a conscious decision to consider this difference during the production process. Many physicians from Dharamsala noted that they use the old Tibetan texts to do their own research for finding the new combinations and establishing the efficacy of the existing ones.
While demand for Tibetan Medicine is on the rise, there are supply constraints. Both locals and tourists demand Tibetan medicines; questions have arisen as to whether better packaging and format (pills and powder) would facilitate their trust. For example, a popular physician from Ladakh (India) mentions:
I would put English and Ladakhi on the packet. Demand will increase when patients know what is inside the medicine. If I could pack powders in this way, then the National Rural Health Mission (NRHM-the government health functionary) would supply them to the public hospitals. They need something that lasts long time, is easy to prescribe and easy for patients to take. If I show this packet, they will surely ask me to bring it. This could be the next step that will bring me success.
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He thought that transparent information about the product is also relevant. At the same time, he mentioned that any kind of innovation is expensive and for the individual physicians it is difficult to manage within the limits of their earning.
The above conversations narrate some of the evidences for non-patented but meaningful innovations in Tibetan medicine. Although such innovations in Tibetan medicine may fall well below the radar of scientific innovations and existing patent requirements, without doubt, they have larger repercussions in crafting a niche for Tibetan medicine and its practitioners. These inexpensive but effective frugal innovations (below the radar) may be imperfect, but have a wider outreach and are not limited to low-resource settings: ingenuous ideas can be adapted to offer simpler and efficient alternatives to mainstream care. This is important as many international organizations justify the promotion of indigenous medicines mainly on economic grounds like low-cost access to medicines and universal health coverage (WHO, 2002 (WHO, , 2013 WIPO, 2013) . In this process, the national and international health policies tend to equate the "medical" space of traditional medicines to that of biomedicine. Yet, it is important to mention that Tibetan medicine has been able to maintain somewhat more conceptual and epistemological autonomy than other Asian medical systems (e.g., Janes, 1995 Janes, , 1999 in this phase as it is even now being mostly practiced by the traditional physicians and less commodified in comparison to other Asian medicines. After having illustrated the notions of Tibetan medicine and below the radar innovations within the same, the article now considers conceptualizations of Tibetan medicine as an economic property (section 4) and, after a scrutiny of Chinese and Indian laws governing the same (section 5) as a form of intangible cultural heritage (section 6).
| TIBETAN MEDICINE AS ECONOMIC PROPERTY
This section examines the conceptualization of Tibetan medicine as an economic property in the world pharmaceutical market. Of many factors, the increasing cost of drug discovery and off-patent debacle of 2012-2015 7 and the MADHAVAN | 243 consequent exigency for herbal formulations made many pharmaceutical companies to renew their strategies in favor of indigenous knowledge based drug development. Rausser and Small (2000) pointed out that the contribution of traditional codified or non-codified medical knowledge largely enhances the probability of drug development at the lead discovery stage (sometimes as high as 50% chance of success), and thereby reducing attendant costs and time taken for the initiation of the drug development process. Although critics suggest that the chemical complexity of natural products may make commercial production expensive or impossible (Firn, 2003) , bioprospection is often used as a pertinent direction of research in many pharmaceutical companies.
Among codified systems, Chinese medicine and Ayurveda (a system of traditional medicine with historical roots in Indian subcontinent), are more commercialized and frequently subject to bioprospection (Patwardhan & Mashelkar, 2009) Sowa Rigpa is at a nascent stage of industrial development compared to Ayurveda and Chinese medicine, but a number of firms have started its mass production, mostly Tibet based companies in China but also in India, Mongolia, Inner Mongolia, and Switzerland. There are some initial attempts to map and narrate the modernization, institutionalization, and industrial formation of this system in specific areas (Blaikie, 2013; Kloos, 2013 Kloos, , 2015 Saxer, 2013) . Even though in indigenous medicines, the actual expenditure on research and development (R&D) is considered to be less than the mainstream pharmaceutical sector (Madhavan, 2011) , now there is an increasing attempt by larger pharmaceutical corporates to invest in R&D on herbal formulations. As a result, patented medicines, either through active compound research or reverse engineering are of high priority in Chinese medicines and Ayurveda. In this context, the Tibetan medicine with its huge volume of unexplored knowledge can potentially be treated as an economically tradeable commodity and hence patenting is obviously considered as an indicator for increasing research attempts and a prevailing form of assurance to market profitability. Interestingly most of them are filed in the last decade. The number of granted applications is listed in Table 1 .
What is important is that a large number of patents are applied and awarded in Chinese, US, and European patent offices, which claimed a close or remote reference to Tibetan formulae. This, prima facie, underlines the increasing attempt to claim the property ownership over many formulas in Tibetan medicine. How many have been actively converted into the industrial application is not evident. But this can lead to restricted use of even the traditional formulas and for sure lead to further drug development or bioprospection possibilities and hence it may change the course of the industrial structure from a very petty commodity, proto-industrial system to a monopolistic competition.
This has a critical impact on the property rights systems within the sector as well, as many of these home-based physicians' informal innovations might be challenged by the new industrial ownership claims. Most of these patent applications are filed by Chinese corporates and even most of the patents on "Mongolian medicine"-another search term we have used-also emerge from these groups. A path dependent development strategy of traditional Chinese medicine (TCM) is apparent in China's policies towards Tibetan formulas. The major disease categories in which the medicines fall in are diabetes, peptic ulcer, hyperlipidemia, kerato conjunctivitis, influenza, cough, hypertension, chronic bronchitis, hemorrhoids, pharyngitis, etc., and the patents are claimed by the researchers or corporate institutions, which mostly are part of the production units in China include both Tibetan and Chinese owners. one of the big concerns is the granting of wrong patents to the multinational corporations, while various communities and individuals practice the same knowledge for years.
While patents remain as a foremost indicator that visualizes Tibetan medicine as an economic property, the second is increasing number of Randomized Control Trails (RCTs) in Tibetan medicine research (see Figure 1) . One recent research found that a total of 227 RCTs involving 29,179 participants were reported in China, which differs in terms of study size, sites, treated conditions, interventions, measured outcomes, and quality (Luo et al., 2015) .
According to the study, 103 diseases or symptoms were reported in the included trials. Medical interventions used in the RCTs consisted of drug treatments and non-drug treatments including bloodletting and moxibustion in which And article 19 gives special permission to the certified firm to allow/license other firms to duplicate their medicines with a certain mutually agreeable amount of royalty.
However, the exclusive right of production of traditional formulations to some companies in the second category led to a legal dispute within China itself. So called precious pills 10 like Rinchen Ratna Samphel, Rinchen mangjor and Rinchen
Drangjor were allowed to be produced only by TAR Tibetan medicine factory in Lhasa and Arura group in Xining. This, in turn led to a major fight between Dr. Jigme Phuntsog (An influential lama of the Nyingma tradition of Tibetan Buddhism and owner of the second largest Tibetan medical company in Xining) on the production rights of the first two precious pills by Arura group for 14 years with a renewed second-class protection. Dr. Phuntsog questioned the government and defended his fundamental right of practicing the monastery learned knowledge, but failed in the legal attempt. This showed that the state mechanism to provide the exclusive trade rights for classical products to one particular company actually entered into the rights of the many who have experience in practice and making of the same medicine.
In China, formulas officially documented and locally registered before 1997 are granted the status of "old"
knowledge. All other oral and textual knowledge is treated as a new knowledge and not listed in the Tibetan medicine standards and Chinese pharmacopeia until they are proven through comprehensive scientific studies. In reality the distinction is not between new and traditional, but between already documented, filtered, and approved knowledge and that which is yet to undergo that process (Saxer, 2013 ). The fact is that the window of undergoing the process of MADHAVAN | 247 documentation was kept as low as possible and hence large part of oral knowledge is obliged to produce new scientific evidence to enter the pharmaceutical market. The scientific research necessary for this registration costs between $300,000 and $1.4 million per drug.
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This complexity in the property assignment and imbalance in the power relations is of serious concern. The regulatory requirements in China go beyond what is required in India and in Europe. Hence, many formulas are not locally registered and officially documented, fall outside the Tibetan drug standards and subjected to increasing pressure to comply with Chinese state food and drug administration and GMPs. As the patent paradigm enjoys the expediency of an internationally established legal protection and recognition, it is understandable that China is increasing the share of patent protection with in Chinese and the Tibetan medicine sector, while the other portion of domesticated sui-generis applications are shrinking over the years.
In China, patents are also used in an effective way to improve the shortcomings of the traditional formulations as well. They actually help in overcoming the "incompatibilities" of ancient preparations for the market, for example, the Huoxiangzhengqi liquid, even though very effective, but the taste was difficult for many patients due to the residual alcohol. The technology of Patent No. 91107254.3 effectively solved the problem of high amount of ethanol in the oral liquid (Saxer, 2013) . Bunao jianshen pill, as one of the classic ancient prescriptions in Shandong, was used for brainstrengthening and Kidney-nourishing, but it had the problem of market promotion because its cinnabar coating contained heavy metals like mercury. The technology of patent No. 94110752.3 had solved this problem of cinnabar coating.
Since the Tibetan medicine in china is driven by the policies applicable to traditional Chinese medicine, it is interesting to note the definitions of various terms used in the patent clause. Under article 25 of the Chinese Patent Law 1992, traditional medicine can be protected through three categories-products, usage and methods. Under "products" the following can be covered: TCM prescription, herb, relevant product, medicinal compound with its active compounds. Under "usage" new medical use can be covered while under "methods" processes like extracting, preparation, and formulation can be covered. Thus, both product patents and process patents are available for protecting TCM. Under the Article 22 of Chinese Patent Law, the criteria are defined as:
Novelty means that, before the date of filing, no identical invention ... has been publicly disclosed in publications in the country or abroad or has been publicly used or made known to the public by any other means in the country (not abroad), nor has any other person filed previously with the Patent Administration Department Under the State Council an application which described the identical invention and was published after the said date of filing. Inventiveness means that, as compared with the technology existing before the date of filing the invention has prominent substantive features and represents a notable progress.
Practical applicability means that the invention can be used to produce effective results (PRC, 2008) .
Besides the above criteria, applicants have to provide full description of the invention (disclosure of methods but not origin) so that anyone skilled in the art is capable to carry it out. 12 From the above statements, it is evident that the knowledge in use outside the country could be patented in China, as novelty clause is defined in a very narrow sense.
Since only methods are revealed and not origin, the question of prior informed consent and details of appropriation may remain hidden. These definitions in the patent regulations may give ample room for illegitimate appropriation of knowledge in Tibetan medicine practiced outside of China.
In India, Tibetan medicine was accepted in 2010 within the legal framework of Indian medical systems and hence the production regulations are expected to be placed under the Drugs and Cosmetic act (DCA) 1940, with minor amendments. The department related parliamentary standing committee on health and family welfare of Government of India stated that 13 :
The Committee observes that keeping in view the distinct nature and functionality of Tibetan medicines, the same should be defined separately with specific provisions for their regulation, surveillance and monitoring under the scope of the Drugs and Cosmetics Act and Rules on the pattern of other Ayurveda, Siddha and Unani drugs (AS&U) from the outset. The Committee, therefore, recommends that suitable modifications may be made to the Drugs and Cosmetics Act and Rules (para 6.16).
In India, a sui generis system was set up to provide grassroots innovators an incentive to disclose knowledge and origin (GoI, 2002) . AYUSH department have been funding for many documentation efforts on different systems of medicines including Sowa Rigpa. A pharmacopeia compilation has also been initiated in India. The system in India is different from China as the DCA recognizes three categories of protection like patented medicines, proprietary medicines, and classical medicines separately with different regulations. The Tibetan medicines are yet to be defined in the same way, but the process is underway.
DCA defines the classical drugs as:
Ayurvedic, Siddha or Unani drug includes all medicines intended for internal or external use for or in the diagnosis, treatment, mitigation or prevention of [disease or disorder in human beings or animals, and manufactured] exclusively in accordance with the formulae described in, the authoritative books of Ayurvedic, Siddha and Unani (Tibb) systems of medicine], specified in the First Schedule (with an amendment in 1982)
Proprietary medicines as:
In relation to Ayurvedic, Siddha or Unani Tibb systems of medicine all formulations containing only such ingredients mentioned in the formulae described in the authoritative books of Ayurveda, Siddha or Unani Tibb systems of medicine specified in the First Schedule, but does not include a medicine which is administered by parenteral route and also a formulation included in the authoritative books as specified in clause (a) (GoI, 1940) .
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In the first case of classical (shastric) drugs, no change in the name of the products, ingredients, indications are allowed, proof of efficacy is not required and should not be advertised in public media while the second type can have change of the combinations, but the ingredients should be mentioned in the text and can have brand names along with product names, proof of efficacy is required and can be advertised through public media. In India, there are ambiguities regarding the approval for proprietary medicines as it is filed and approved through the district officers, and state drug controllers and state ISM directorates. With small number of staff in these departments, how efficiently the proof of efficacy and the prior art search are done is still a matter of concern. However, what I intend to emphasize here is, the Indian regulatory system at least provides a room for traditional formulations to thrive and a system in place to promote the grass-root and family based innovations/formulations.
Section 6(i) of the Biological Diversity Act of India, 2002 (GoI, 2002 and the Patents Act, 1970 15 requires an applicant to obtain the necessary permission from the National Biodiversity Authority before applying for a patent for any invention based on biological resources obtained from India. The process of granting such approvals by the National Biodiversity Authority is carried out in consultation with the State Biodiversity Boards, if necessary. Even though the ownership of the State over the biological resources and the difficulties it poses to the Ayurvedic firms being questioned (Agarwal, 2001) , now the traditional knowledge digital library (TKDL) and biodiversity management committees (safeguarding and managing the documentation the knowledge in different panchayats through biodiversity registers)
has become an integral part of effective monitoring system of traditional knowledge innovations.
The reverse engineering and phyto-medical approaches in drug discovery has impelled the process of herbalization and alienation from its epistemological roots, but only projects its market efficiency through a property rights system. Tibetan medical formulas (which largely rely on herbs, minerals, and animal ingredients) now may be projected as a part of herbal system with US or European patents to tap the global market for "natural" medicines. The MADHAVAN | 249 patent statistics might be an indication towards the same. Strict scientific approach stripping its theoretical plurality would win the markets for herbal medicines as seen in the success story of Japan and Germany as leading suppliers of herbal medicines and botanical medicines (Hsiao, 2007) .
16

| TIBETAN MEDICINE AS CULTURAL PROPERTY
The 1970 UNESCO convention prohibit and prevents the illicit and illegal import, export and transfer of ownership of cultural property. 16 These obligations called for States "to protect the cultural property within [their] territories against dangers of theft, clandestine excavation and illicit export." States are asked to undertake practices with whatever means they have at their disposal to assist in making necessary reparation, and to prevent the illicit trade and transfer. The convention provides for States to designate items that are of cultural importance. These items have to be of importance in archaeology, prehistory, history, literature, art or science, rare collections and hence naturally, the specimens of fauna, flora, minerals and anatomy, and objects of paleontological interest are protected. The Convention allows source nations to create an institutional structure for protecting their cultural property and define "illicit" in any terms they wish, and
Member States must enforce the export laws of foreign States (Veres, 2014) . The concept of cultural property has been successfully used at the national level for protection of Tibetan medicine in China.
The increasing concern of globalization and the threat it may pose to the traditional cultural expressions (TCEs) and popular culture culminated in a mechanism to safeguard TCEs at the international level. provincial level, city level, and country level protection elements. The system included naming, awarding, commendation, reward, and other ways for protecting ICH and representative inheritance persons in China.
Tibetan medicine was one among the nine medicine-related cultural heritages 19 created in 2008, and so far medicine including Chinese, Tibetan, and Mongolian medicine forms 3.7% of all Chinese intangible heritages (Ye & Zhou, 2013) . But a close analysis of the document of Tibetan medicine in the Chinese intangible heritage application shows that the main Tibetan treatise, Gyushi is mentioned only in passing in the last paragraph of the English version (aimed at the international readers) and the Chinese version is presented in a much different way and highlights techniques of mercury processing in Tibetan medicine (Obringer, 2011) . Gerke (2013) and Saxer (2013) international instrument relating to IP rights or to the use of biological and ecological resources to which they are parties (Vadi, 2007) . Considering knowledge as a "public good," unlike the biological resources, its shared use need not be curtailed or confined. Simultaneous use of a public good like knowledge either can improve the ways of utilizing the knowledge or can find a better use instead of "tragedy of commons," which can happen in the case of biological resources. So as a sustainable protection mechanism, the use of one country's cultural heritage application for a traditional knowledge, normally should not affect the right to use this knowledge by other country that shares the same cultural heritage. It can create some tensions or conflicts among those nations who shares a type of ICH. The engagement of local communities in these applications needs to be ensured by the nominating nations.
Many plants and natural products of the Tibetan pharmacopoeia are either endemic or already limited to certain protected areas. This raises the question of how an increased demand for such products would be handled. Providing ICH rights to any particular country less likely to hinder the free flow of resources, as article 3 of the ICH convention mentions that the convention does not alter the obligations under the other international law instruments such as TRIPS agreement (Vadi, 2007) , unless economic sanctions are forced upon the traded materials. This is possible either due to an increasing pressure for raw material protection or due to political conflicts regarding the ownership of knowledge. China proposes a "Productivity-based
Protection," that is the ICH and the resources thereof are transformed into products through manufacturing, circulation, and distribution, so that the economic benefits are available and so the development of related industries is possible. They argue, like many others, that the ICH can be positively protected through production practice and a favorable interaction between the intangible cultural heritage and the coordinated social and economic development can be achieved.
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Protection of ICH also has implications in terms of researchers' freedom to deal with the ICH categories.
Foreigners will need approval from the provincial level authorities before they can conduct any surveys involving ICH and such research must be done in co-operation with Chinese research institutions, and reports must be made on the results. Copies of field notes and pictures must also be submitted to provincial authorities. The individual researchers who violate the rules may be subject to fine about US $1500-7600, while the organizations may be fined ten times of this amount. Some sort of monitoring also holds true with biological diversity rules in India. It also states that the resources would be owned by the State and any industrial usage needs two levels of permission from the national biodiversity authority and the state management committees. The biodiversity rules in India have already raised the eyebrows of the manufacturing associations of Indian medicines, as it poses multiple hurdles in accessing the resources. There is no doubt that the economics of these cultural resources attains more attention than ever before.
What I argue is that there is an economic intention behind most of the protection possibilities, either through existing intellectual property coverage or through the ICH approach. In the neo-classical economic model, even though the patent monopoly is justified by benefit to the public, it alters the competitive environment between the market players. The winner takes the entire market outcompeting the established market actors, which allows the market powers to consolidate their
power through new forms of research. On the other hand, the innovations in Tibetan medicine are of different genre. These cumulative innovations include improvements in existing medicines, finding new processes that are not covered by patents, compounds with slightly different properties or new forms, mostly added through experience and public feedback. Such innovations may fail to meet a high threshold of inventive step, as the invention is not of technological nature beyond the prior art. Nevertheless, in a situation where there is no product patent or where the length of the patent is shorter, such innovations are used to bring in cheaper and effective generic equivalents (Srinivas, 2013) . How far local resistance can change the fate of negative impacts of global property right regimes is doubtful, though Pordie (2008) argues that in the Ladakh Himalayan region, although the local protagonists agree to follow the protection policy, they redefined its meaning and purposes in such a way to serve their interests on the level of their community, reaffirming their ethnicity and medical identity. Such kind of local alternatives needs to be empowered.
A significant number of Tibetan medical practitioners have been ignored under the category of local health
Traditions with no public support and regulations, while they remain in high demand due to the low cost but effective healthcare options. The local technological capability of many small medicine producers is not adequate enough to either effectively implement the new regulative structures or complete in the commodification phase. Healthcare policy researchers argue that a strong national capability for both technological and social innovation in developing countries represents the only truly sustainable means of improving the effectiveness of health systems (Gardner, Acharya, & Yach, 2007) . Benefiting from this commodification depends not only on the availability of legal rights that are enforceable beyond the locality, but also on the ability of traditional knowledge holders to take advantage of the national and international law including property and access rights relating to the resources, land, and intellectual property (Dutfield, 2005) . The last two sections showed that how effectively China has developed an institutional infrastructure for protecting their cultural property while India has enacted the sui-generis laws to make the traditional formulas and innovations inclusive within the existing property right framework. There are multiple rights that need to be balanced in Tibetan medicine, (a) the rights of traditional Tibetan physicians to practice and to access the medicinal plants; and (b) access to medicines by the public; (c) the rights for incremental innovations or new formulations developed from long term practice; (d) the protection from biopiracy threats from foreign patenting companies and importantly; and (e) the rights of the stakeholders when they share the tradition beyond geographical boundaries, etc. We have seen that the property approaches of China and India gives weight to selective stakeholders in different contexts. The Indian biomedical Pharmaceutical market have shown that national property regimes can boost the domestic industry and reach the global market (Kumar, 2002; Rasiah, 2002; Watal, 2000) . The technological advance achieved by the Indian pharmaceutical industry owes much to the 1970 Patents Act 21 and subsequent legalized reverse engineering of patented molecules. These reforms contributed many tangible benefits such as the creation of manufacturing capacities, lower medicine prices, and availability of medicines to the masses, hence more social benefits.
The national economies have their own mechanism of protection and a well-structured institutional infrastructure to support Tibetan medicine as in China. Whether an economic or cultural property approach would benefit in this direction is not clear, but a sui-generis mechanism should perform the dual responsibility of property right regime as a defensive mechanism against bio-piracy threats and unfair exploitation and as a protective mechanism for grass root innovations and local resources in the context of increasing transnational patent applications and appropriations.
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